SG Americas Securities LLC Sells 11,198 Shares of ResMed Inc. (NYSE:RMD)

SG Americas Securities LLC trimmed its holdings in ResMed Inc. (NYSE:RMDGet Rating) by 76.2% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 3,490 shares of the medical equipment provider’s stock after selling 11,198 shares during the quarter. SG Americas Securities LLC’s holdings in ResMed were worth $846,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Copeland Capital Management LLC increased its holdings in ResMed by 4.8% in the 1st quarter. Copeland Capital Management LLC now owns 5,473 shares of the medical equipment provider’s stock worth $1,327,000 after buying an additional 253 shares in the last quarter. Greenleaf Trust increased its holdings in ResMed by 10.7% in the 1st quarter. Greenleaf Trust now owns 2,250 shares of the medical equipment provider’s stock worth $546,000 after buying an additional 218 shares in the last quarter. CIBC Asset Management Inc increased its holdings in ResMed by 3.9% in the 4th quarter. CIBC Asset Management Inc now owns 14,838 shares of the medical equipment provider’s stock worth $3,865,000 after buying an additional 552 shares in the last quarter. BlackRock Inc. boosted its position in ResMed by 2.8% in the fourth quarter. BlackRock Inc. now owns 13,048,735 shares of the medical equipment provider’s stock worth $3,398,935,000 after purchasing an additional 360,161 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in ResMed by 4.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,717 shares of the medical equipment provider’s stock worth $12,784,000 after purchasing an additional 2,365 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors.

ResMed Stock Down 1.0 %

RMD stock opened at $240.52 on Monday. ResMed Inc. has a twelve month low of $189.40 and a twelve month high of $301.34. The company has a quick ratio of 1.56, a current ratio of 2.55 and a debt-to-equity ratio of 0.20. The stock has a market cap of $35.18 billion, a P/E ratio of 45.30, a PEG ratio of 2.27 and a beta of 0.42. The business’s 50-day moving average price is $213.84 and its 200-day moving average price is $226.11.

ResMed (NYSE:RMDGet Rating) last posted its quarterly earnings results on Thursday, April 28th. The medical equipment provider reported $1.32 EPS for the quarter, missing analysts’ consensus estimates of $1.44 by ($0.12). ResMed had a return on equity of 26.91% and a net margin of 22.02%. The business had revenue of $864.50 million during the quarter, compared to analysts’ expectations of $900.03 million. During the same period in the prior year, the firm posted $1.30 earnings per share. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, equities research analysts forecast that ResMed Inc. will post 5.75 EPS for the current year.

Insider Buying and Selling

In related news, CFO Brett Sandercock sold 7,500 shares of the business’s stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $235.00, for a total value of $1,762,500.00. Following the transaction, the chief financial officer now directly owns 106,426 shares of the company’s stock, valued at approximately $25,010,110. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other ResMed news, CEO Michael J. Farrell sold 5,675 shares of ResMed stock in a transaction that occurred on Friday, July 15th. The stock was sold at an average price of $224.94, for a total value of $1,276,534.50. Following the sale, the chief executive officer now owns 405,260 shares of the company’s stock, valued at approximately $91,159,184.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Brett Sandercock sold 7,500 shares of ResMed stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $235.00, for a total value of $1,762,500.00. Following the completion of the sale, the chief financial officer now directly owns 106,426 shares in the company, valued at approximately $25,010,110. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,160 shares of company stock valued at $6,264,845. Corporate insiders own 1.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on RMD shares. Wolfe Research started coverage on ResMed in a research report on Tuesday, April 5th. They issued an “outperform” rating and a $280.00 target price on the stock. StockNews.com cut ResMed from a “buy” rating to a “hold” rating in a research report on Thursday, June 16th. Finally, Royal Bank of Canada raised ResMed from a “sector perform” rating to an “outperform” rating and raised their target price for the stock from $233.00 to $244.00 in a research report on Monday, June 6th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $264.80.

ResMed Company Profile

(Get Rating)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Recommended Stories

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Want More Great Investing Ideas?

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.